Puretech receives orphan drug designation for wholly owned candidate lyt-200 for the treatment of pancreatic cancer

Boston--(business wire)--puretech announces that the u.s. fda granted orphan drug designation for lyt-200 for the treatment of pancreatic cancer.

PRTC Ratings Summary

PRTC Quant Ranking